Online inquiry

IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11238MR)

This product GTTS-WQ11238MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets pcrV&psl gene. The antibody can be applied in P. Aeruginosa nosocomial pneumonia research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq WP_003100789.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID O30527
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11238MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4611MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ1043MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ204MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ12471MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ8898MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IGE25
GTTS-WQ8127MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HH1
GTTS-WQ2032MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ12042MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MNRP1685A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW